These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 10699348)

  • 1. "Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants" by samantha D. Rencher, timothy D. Lockey, ranga V. Srinivas, randall J. Owens and julia L. Hurwitz. Vaccine 15(3) pp. 265-272 (1997).
    Vaccine; 2000 Mar; 18(18):1969. PubMed ID: 10699348
    [No Abstract]   [Full Text] [Related]  

  • 2. Ultraviolet-irradiated vaccinia virus recombinants, exposing HIV-envelope on their outer membrane, induce antibodies against this antigen in rabbits.
    Loewinger M; Katz E
    Viral Immunol; 2002; 15(3):473-9. PubMed ID: 12479396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus.
    Morrison HG; Bauer SP; Lange JV; Esposito JJ; McCormick JB; Auperin DD
    Virology; 1989 Jul; 171(1):179-88. PubMed ID: 2741340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants.
    Rencher SD; Lockey TD; Srinivas RV; Owens RJ; Hurwitz JL
    Vaccine; 1997 Feb; 15(3):265-72. PubMed ID: 9139484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.
    Cooney EL; Collier AC; Greenberg PD; Coombs RW; Zarling J; Arditti DE; Hoffman MC; Hu SL; Corey L
    Lancet; 1991 Mar; 337(8741):567-72. PubMed ID: 1671940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.
    Lockey TD; Slobod KS; Caver TE; D'Costa S; Owens RJ; McClure HM; Compans RW; Hurwitz JL
    Immunol Res; 2000; 21(1):7-21. PubMed ID: 10803879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus.
    Hu SL; Zarling JM; Chinn J; Travis BM; Moran PA; Sias J; Kuller L; Morton WR; Heidecker G; Benveniste RE
    Proc Natl Acad Sci U S A; 1989 Sep; 86(18):7213-7. PubMed ID: 2550935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
    Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1.
    Slobod KS; Lockey TD; Howlett N; Srinivas RV; Rencher SD; Freiden PJ; Doherty PC; Hurwitz JL
    Eur J Clin Microbiol Infect Dis; 2004 Feb; 23(2):106-10. PubMed ID: 14735404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62.
    Lowry PW; Solem S; Watson BN; Koropchak CM; Thackray HM; Kinchington PR; Ruyechan WT; Ling P; Hay J; Arvin AM
    J Gen Virol; 1992 Apr; 73 ( Pt 4)():811-9. PubMed ID: 1321876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector.
    Gómez CE; Rodríguez D; Rodríguez JR; Abaitua F; Duarte C; Esteban M
    Vaccine; 2001 Dec; 20(5-6):961-71. PubMed ID: 11738764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeras between the human immunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate in mice broadly reactive antibodies and specific activation of CD8+ T cell responses to Env.
    Collado M; Rodríguez D; Rodríguez JR; Vázquez I; Gonzalo RM; Esteban M
    Vaccine; 2000 Jul; 18(27):3123-33. PubMed ID: 10856792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team
    J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.
    Kilgore KM; Murphy MK; Burton SL; Wetzel KS; Smith SA; Xiao P; Reddy S; Francella N; Sodora DL; Silvestri G; Cole KS; Villinger F; Robinson JE; Pulendran B; Hunter E; Collman RG; Amara RR; Derdeyn CA
    J Virol; 2015 Aug; 89(16):8130-51. PubMed ID: 26018167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the parental virus strain on the virulence and immunogenicity of recombinant vaccinia viruses expressing HBV preS2-S protein or VZV glycoprotein I.
    Kutinová L; Ludvíková V; Krystofová J; Otavová M; Simonová V; Nĕmecková S; Hainz P; Vonka V
    Vaccine; 1996 Aug; 14(11):1045-52. PubMed ID: 8879101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions.
    Katz E; Moss B
    AIDS Res Hum Retroviruses; 1997 Nov; 13(17):1497-500. PubMed ID: 9390748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
    Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
    J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge.
    Men R; Wyatt L; Tokimatsu I; Arakaki S; Shameem G; Elkins R; Chanock R; Moss B; Lai CJ
    Vaccine; 2000 Jul; 18(27):3113-22. PubMed ID: 10856791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.